NASDAQ$CYRX
CryoPort Inc. · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Cryoport's Q4 2021 financial results were reported, showing revenue growth driven by Cryoport Systems and CRYOGENE.
Cryoport reported a 17% increase in revenue for Q4 2021, reaching $56.4 million. This growth was primarily driven by a 34% increase in organic revenue from Cryoport Systems and CRYOGENE. The company supports 602 clinical trials and 8 commercial therapies.
- Q4 revenue reached $56.4 million, a 17% increase year-over-year.
- Organic revenue from Cryoport Systems and CRYOGENE grew by 34%.
- Cryoport supports 602 clinical trials and 8 commercial therapies globally.
- Biopharma/Pharma revenue increased 18% year-over-year.
Headline financials
Revenue & EPS history
CryoPort · Revenue · Quarterly
$56.4M
Forward guidance
Cryoport anticipates up to nineteen additional filings, four new therapy approvals, and an additional six label or geographic expansion approvals in 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+2.2%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
49%
28 / 57 earnings
Positive
+31.6%
Q4 2013
Best reaction
-33.8%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.4% | +33.2% | +58.2% | |
| Q4 2025 | +2.9% | -4.7% | +3.3% | |
| Q3 2025 | -8.2% | -7.4% | +3.5% | |
| Q1 2025 | +23.4% | +23.3% | +23.7% | |
| Q4 2024 | +30.6% | -7.1% | +5.7% | |
| Q3 2024 | -3.6% | -0.9% | -8.6% | |
| Q2 2024 | +3.9% | +10.0% | +9.8% | |
| Q1 2024 | -17.5% | -16.7% | -30.6% | |
| Q4 2023 | -12.3% | -7.3% | +10.3% | |
| Q3 2023 | +8.9% | +8.4% | +46.7% | |
| Q2 2023 | -0.2% | +1.2% | -5.0% | |
| Q1 2023 | +13.9% | +4.5% | -6.3% | |
| Q4 2022 | +13.7% | +9.9% | +15.3% | |
| Q3 2022 | -33.8% | -35.7% | -26.5% | |
| Q2 2022 | +6.8% | +5.2% | -16.1% | |
| Q1 2022 | -8.5% | -14.6% | -2.8% | |
| Q4 2021 | +9.3% | +7.0% | +1.9% | |
| Q3 2021 | -1.0% | -1.2% | -22.8% | |
| Q2 2021 | -1.5% | -3.6% | +2.9% | |
| Q1 2021 | +9.0% | +11.6% | -2.4% | |
| Q4 2020 | -0.7% | -11.7% | -12.5% | |
| Q3 2020 | +5.0% | +24.2% | +12.8% | |
| Q2 2020 | -2.0% | -5.0% | +55.5% | |
| Q1 2020 | +2.0% | +17.0% | +22.6% | |
| Q4 2019 | +2.1% | +0.8% | -11.9% | |
| Q3 2019 | +1.4% | +3.9% | +5.6% | |
| Q2 2019 | +19.7% | +24.5% | +2.3% | |
| Q1 2019 | +12.5% | +12.5% | +17.7% | |
| Q4 2018 | -0.6% | +6.6% | +22.3% | |
| Q3 2018 | -1.0% | -9.4% | -2.0% | |
| Q2 2018 | -1.6% | -14.7% | -6.5% | |
| Q1 2018 | +11.8% | +23.0% | +67.4% | |
| Q4 2017 | +3.8% | +6.4% | -7.0% | |
| Q3 2017 | -15.1% | -22.9% | -10.5% | |
| Q2 2017 | -2.0% | +3.6% | +28.6% | |
| Q1 2017 | +8.2% | +9.0% | +46.9% | |
| Q4 2016 | +23.7% | +9.0% | +23.7% | |
| Q2 2016 | -7.5% | — | — | |
| Q1 2016 | +10.2% | — | — | |
| Q4 2015 | -3.0% | — | — | |
| Q3 2015 | +7.5% | — | — | |
| Q2 2015 | -14.4% | — | — | |
| Q1 2015 | -2.2% | — | — | |
| Q4 2014 | +6.4% | — | — | |
| Q3 2014 | -5.6% | — | — | |
| Q4 2013 | +31.6% | — | — | |
| Q3 2013 | -8.0% | — | — | |
| Q2 2013 | +5.3% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | -3.1% | — | — | |
| Q3 2012 | -10.8% | — | — | |
| Q2 2012 | -8.0% | — | — | |
| Q1 2012 | -2.7% | — | — | |
| Q1 2010 | +11.2% | — | — | |
| Q3 2009 | +1.4% | — | — | |
| Q2 2009 | -2.8% | — | — | |
| Q1 2009 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro